EPO published patent application EP3664893A1 for hemopexin therapeutic formulations, classifying under A61P 7/04 (hematological agents) and A61K 38/16/17 (proteins). CSL Behring AG is the applicant with five named inventors. The patent designates 31 European states covering major pharmaceutical markets.

This patent publication grants CSL Behring exclusive intellectual property rights to hemopexin formulations in designated territories. Competing entities developing hemopexin-based therapeutics should assess freedom-to-operate implications and consider licensing discussions with CSL Behring if pursuing similar products. No compliance actions are required, but IP and R&D teams should review the patent scope for relevance to current development programs.